Preyas J. Vaidya
Preyas J. Vaidya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Prashant Nemichand Chhajed
Institute of Pulmonology, Medical Research and Development, Mumbai, Maharashtra, India
2 shared publications - Anne Barbara Leuppi-Taegtmeyer
Department of Patient Safety, Medical Directorate, University Hospital Basel, Basel, Switzerland.
1 shared publication Atul C. Mehta
Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publicationJoerg D. Leuppi
Department of Internal Medicine, Kantonsspital Baselland, Liestal, Basel, Switzerland
1 shared publication- Joerg Daniel Leuppi
University Institute of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland
1 shared publication Mohammed Munavvar
Department of Pulmonary Medicine, Lancashire Teaching Hospitals, Preston, UK
1 shared publication
Latest Publications
- 14 January 2020
- Published by S. Karger AG in Respiration
- Vol. 99 (2) , 125-131
High Incidence of New-Onset Joint Pain in Patients on Fluoroquinolones as Antituberculous Treatment
Background: Joint pain is frequently observed in patients on antituberculous treatment, and pyrazinamide is known to be associated with joint pain in patients receiving antituberculous treatment. Fluoroquinolone-associated joint pain and tendon injury have been reported in long-term corticosteroid and transplant recipients, but data are lacking in patients with tuberculosis. Objectives: The objective of this study was to examine the incidence of joint pain manifested during administration of antituberculous therapy and their association with fluoroquinolones. Methods: Patients diagnosed with tuberculosis attending the outpatient clinic over a period of 1 year were reviewed and divided into 3 groups: group A receiving pyrazinamide, group B receiving a fluoroquinolone, and group C receiving both pyrazinamide and a fluoroquinolone. Latency to onset of joint pain was noted in all 3 groups. Joint pain was initially managed with analgesics, and associated hyperuricemia was treated with allopurinol/febuxostat. Causative drugs were stopped in case of intolerable joint pain. Results: 260 patients (47% females, aged 38 ± 18 years; mean ± SD) were included [group A (n = 140), group B (n = 81), and group C (n = 39)]. Overall, 76/260 (29%) patients developed joint pain: group A – 24/140 patients (17%), group B – 32/81 patients (40%), and group C – 20/39 patients (51%). The median latency to the onset of joint pain was 83 days (interquartile range, IQR 40–167): 55 days (IQR 32–66) in group A, 138 days (IQR 74–278) in group B, and 88 days (IQR 34–183) in group C. Hyperuricemia was present in 12/24 (50%) patients in group A and 11/20 (55%) patients in group C. Pyrazinamide was stopped in 7/140 (5%) patients in group A, fluoroquinolones in 6/81 (7%) patients in group B, and both pyrazinamide and fluoroquinolones were stopped in 5/39 (13%) patients in group C because of intolerable joint pain. Major joints affected were knees and ankles. Conclusion: There is a high incidence of joint pain in patients receiving antituberculous treatment, which is higher when fluoroquinolones or the pyrazinamide-fluoroquinolone combination are administered as compared to pyrazinamide alone.
- 14 January 2020
- Published by S. Karger AG in Respiration
- Vol. 99 (2) , 125-131
High Incidence of New-Onset Joint Pain in Patients on Fluoroquinolones as Antituberculous Treatment
Background: Joint pain is frequently observed in patients on antituberculous treatment, and pyrazinamide is known to be associated with joint pain in patients receiving antituberculous treatment. Fluoroquinolone-associated joint pain and tendon injury have been reported in long-term corticosteroid and transplant recipients, but data are lacking in patients with tuberculosis. Objectives: The objective of this study was to examine the incidence of joint pain manifested during administration of antituberculous therapy and their association with fluoroquinolones. Methods: Patients diagnosed with tuberculosis attending the outpatient clinic over a period of 1 year were reviewed and divided into 3 groups: group A receiving pyrazinamide, group B receiving a fluoroquinolone, and group C receiving both pyrazinamide and a fluoroquinolone. Latency to onset of joint pain was noted in all 3 groups. Joint pain was initially managed with analgesics, and associated hyperuricemia was treated with allopurinol/febuxostat. Causative drugs were stopped in case of intolerable joint pain. Results: 260 patients (47% females, aged 38 ± 18 years; mean ± SD) were included [group A (n = 140), group B (n = 81), and group C (n = 39)]. Overall, 76/260 (29%) patients developed joint pain: group A – 24/140 patients (17%), group B – 32/81 patients (40%), and group C – 20/39 patients (51%). The median latency to the onset of joint pain was 83 days (interquartile range, IQR 40–167): 55 days (IQR 32–66) in group A, 138 days (IQR 74–278) in group B, and 88 days (IQR 34–183) in group C. Hyperuricemia was present in 12/24 (50%) patients in group A and 11/20 (55%) patients in group C. Pyrazinamide was stopped in 7/140 (5%) patients in group A, fluoroquinolones in 6/81 (7%) patients in group B, and both pyrazinamide and fluoroquinolones were stopped in 5/39 (13%) patients in group C because of intolerable joint pain. Major joints affected were knees and ankles. Conclusion: There is a high incidence of joint pain in patients receiving antituberculous treatment, which is higher when fluoroquinolones or the pyrazinamide-fluoroquinolone combination are administered as compared to pyrazinamide alone.
- 20 June 2017
- Published by Wiley in Respirology
- Vol. 22 (6) , 1093-1101
Endobronchial ultrasound‐guided transbronchial needle aspiration: Safe as it sounds
Real‐time endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) has earned its place as a standard of care in the evaluation of mediastinal and hilar lymphadenopathy. It is a minimally invasive and a safe procedure with high diagnostic accuracy and efficacy. The increased usage of EBUS‐TBNA worldwide has thrown light on its possible complications including death. The complications range from minor to life threatening in few and may occur either early or later in the course after the procedure. The present review summarizes the reported complications from EBUS‐TBNA, their outcome and the modalities used for their management.
- 20 June 2017
- Published by Wiley in Respirology
- Vol. 22 (6) , 1093-1101
Endobronchial ultrasound‐guided transbronchial needle aspiration: Safe as it sounds
Real‐time endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) has earned its place as a standard of care in the evaluation of mediastinal and hilar lymphadenopathy. It is a minimally invasive and a safe procedure with high diagnostic accuracy and efficacy. The increased usage of EBUS‐TBNA worldwide has thrown light on its possible complications including death. The complications range from minor to life threatening in few and may occur either early or later in the course after the procedure. The present review summarizes the reported complications from EBUS‐TBNA, their outcome and the modalities used for their management.